Navigation Links
Prometheus Acquires Exclusive Rights to PROLEUKIN(R) (aldesleukin) in the U.S.
Date:1/26/2010

SAN DIEGO, Jan. 26 /PRNewswire/ -- Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, today announced the execution of a commercialization agreement with Novartis under which Prometheus acquired exclusive rights to distribute, promote and sell PROLEUKIN® (aldesleukin) in the United States. Proleukin is a recombinant human interleukin-2 for treatment in adults with metastatic melanoma and metastatic kidney cancer. Net sales for Proleukin were approximately $75 million in the U.S. in 2009.

Under the terms of the agreement, Novartis received an upfront fee and will receive royalties on net sales of Proleukin in the U.S. Novartis is also eligible to receive potential sales milestone payments. Prometheus will have the option to extend the initial six-year term on an annual basis for up to an additional six years. In addition, the companies will have an option to amend the agreement to include the rest of the world upon the completion of certain conditions.

"This represents a transformational event for Prometheus as we continue to build our oncology presence and execute on our integrated therapeutics and diagnostics business model," said Joseph M. Limber, President and Chief Executive Officer of Prometheus. "We have established ourselves as a leader in the gastroenterology market by offering a complementary portfolio of pharmaceutical and diagnostic products promoted via Prometheus' highly trained sales force. Now, following the recent launch of our three ProOncDx microRNA-based diagnostic tests and the continued development of our emerging and proprietary diagnostics platform, we are well positioned to repeat this success in the oncology market."

A portion of the proceeds from Prometheus' previously announced $260 million Senior Secured Credit Facility was used to finance this transaction.

About Proleukin

PROLEUKIN® (aldesleukin) for injection is a recombinant human interleukin-2 for treatment in adults with metastatic melanoma and metastatic kidney cancer. Proleukin therapy is a form of immunotherapy that enhances the body's natural immune system to help fight these types of cancer. Proleukin has been used for over 10 years in the treatment of metastatic melanoma and over 15 years in the treatment of metastatic kidney cancer (renal cell carcinoma). For complete prescribing information, please visit www.Proleukin.com.

Important Safety Information

Therapy with PROLEUKIN® (aldesleukin) for injection should be restricted to patients with normal cardiac and pulmonary functions as defined by thallium stress testing and formal pulmonary function testing. Extreme caution should be used in patients with a normal thallium stress test and a normal pulmonary function test who have a history of cardiac or pulmonary disease.

Proleukin should be administered in a hospital setting under the supervision of a qualified physician experienced in the use of anticancer agents. An intensive care facility and specialists skilled in cardiopulmonary or intensive care medicine must be available.

Proleukin administration has been associated with capillary leak syndrome (CLS) which is characterized by a loss of vascular tone and extravasation of plasma proteins and fluid into the extravascular space. CLS results in hypotension and reduced organ perfusion which may be severe and can result in death. CLS may be associated with cardiac arrhythmias (supraventricular and ventricular), angina, myocardial infarction, respiratory insufficiency requiring intubation, gastrointestinal bleeding or infarction, renal insufficiency, edema, and mental status changes.

Proleukin treatment is associated with impaired neutrophil function (reduced chemotaxis) and with an increased risk of disseminated infection, including sepsis and bacterial endocarditis. Consequently, preexisting bacterial infections should be adequately treated prior to initiation of Proleukin therapy. Patients with indwelling central lines are particularly at risk for infection with gram positive microorganisms. Antibiotic prophylaxis with oxacillin, nafcillin, ciprofloxacin, or vancomycin has been associated with a reduced incidence of staphylococcal infections.

Proleukin administration should be withheld in patients developing moderate to severe lethargy or somnolence; continued administration may result in coma.

About Interleukin-2

Interleukin-2 (IL-2) is a protein that occurs naturally in the body and plays an important role in activating the immune system. The immune system protects the body from foreign substances, cells, and tissues by responding to and resisting diseases. Proleukin therapy is a genetically engineered or recombinant version of IL-2. Proleukin therapy possesses the same properties as naturally occurring IL-2 and helps activate the immune system to recognize and eliminate certain kinds of cancer cells.

About Prometheus

Prometheus Laboratories Inc. is committed to improving lives through the development and commercialization of novel pharmaceutical and diagnostic products that enable physicians to provide greater individualized patient care. Prometheus is a leader in applying the principles of personalized medicine to the diagnosis and treatment of gastrointestinal diseases and is applying these principles to oncology. Its strategy includes the marketing and delivery of pharmaceutical products complemented by proprietary diagnostic testing services. By integrating therapeutics and diagnostics, Prometheus believes it can provide physicians with a comprehensive solution to treat chronic diseases. Prometheus’ corporate offices are located in San Diego, California.

PROLEUKIN is a registered trademark of Novartis.

ProOncDx is a trademark of Prometheus Laboratories Inc.

SOURCE Prometheus Laboratories Inc.

RELATED LINKS
http://www.prometheuslabs.com
http://www.Proleukin.com

'/>"/>

SOURCE Prometheus Laboratories Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Prometheus Launches ProOnc Dx Cancer Diagnostics
2. Prometheus Announces New Findings Regarding Patients at Risk for Celiac Disease at DDW
3. Prometheus and Rosetta Genomics Announce License and Collaboration Agreement
4. Prometheus Presents Findings From Development of PROMETHEUS(R) IBS Diagnostic, First Blood Test for IBS, at ACG Annual Scientific Meeting
5. Home Medical Equipment Supplier ActivStyle, Inc. Acquires Tampa-Based Advocate Medical Services, Inc.
6. QIAGEN Acquires ESE GmbH
7. Clarient Acquires Applied Genomics, Inc.
8. InterFlex Acquires C&H Packaging From Appleton Paper
9. University of Virginia Acquires New Elekta Technology to Expand Patient Groups That Could Benefit From Gamma Knife Surgery
10. Pharmaceutical Institute Acquires E-Learning Assets from GeneEd, Inc.
11. St. Lukes Hospital Acquires Pioneering Technology From BrainLAB
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/10/2017)... 2017 Hologic, Inc. (Nasdaq: HOLX ... fiscal second quarter ended April 1, 2017 .   ... 666.7% compared to the prior year period as the ... significant gain, while non-GAAP diluted EPS of $0.50 increased ... in constant currency terms.  Excluding the effects of blood ...
(Date:5/10/2017)... Ill. , May 10, 2017 Radiology ... today; unfortunately its costs have also spiraled to the ... being sent to radiology than ever before as the ... diagnosis.  For a patient with lower back pain an ... no anatomical reason for pain, resulting in entirely different ...
(Date:5/9/2017)... 9, 2017  Demonstrating its commitment to representing ... for the Pharmaceutical Research and Manufacturers of America ... companies will now have to meet new research ... eligible to join PhRMA. "By putting ... sending a clear message that being a member ...
Breaking Medicine Technology:
(Date:5/21/2017)... ... May 21, 2017 , ... For ... a cross-disciplinary group of scholars, policymakers, and activists wanting to address equity issues ... is the third book from a recent series of from this conference. ...
(Date:5/19/2017)... ... May 19, 2017 , ... In a continuous effort to ... a luxury online mattress company that specializes in natural and organic latex mattresses, has ... autism organization) for every unique share their recent viral Facebook video receives, ...
(Date:5/19/2017)... ... 2017 , ... The Hill Agencies, a family managed firm that offers insurance ... Valley, is announcing a joint charity initiative with the Boys and Girls Club of ... event. , The Boys and Girls Club of Kern County gives young people in ...
(Date:5/19/2017)... ... 18, 2017 , ... ML Billing, 2016 Billing Company of the Year ... in large group practices, is pleased to announce their 30th anniversary. Not only has ... standard in all aspects of full-service medical billing. This has allowed ML Billing to ...
(Date:5/18/2017)... Angeles, CA (PRWEB) , ... May 18, 2017 , ... ... is now called the HighQ Learning Tab. Due to the rapid expansion of their ... clearly identifying each type of product. Now, the HighQ brand will be any ...
Breaking Medicine News(10 mins):